Karsten Parczyk Selected Research

ZK703

2/2004

Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karsten Parczyk Research Topics

Disease

4	Neoplasms (Cancer) 01/2018 - 02/2004
3	Breast Neoplasms (Breast Cancer) 01/2018 - 05/2003
1	Neoplasm Metastasis (Metastasis) 01/2018
1	Hypoxia (Hypoxemia) 01/2017
1	Skin Diseases (Skin Disease) 01/2008

Drug/Important Bio-Agent (IBA)

2	Fulvestrant (Faslodex)FDA Link 02/2004 - 05/2003
2	Estrogen Receptor Modulators (Antiestrogen)IBA 02/2004 - 05/2003
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	phenothiazineIBA 01/2017
1	AcidsIBA 01/2017
1	Fluphenazine (Prolixin)FDA LinkGeneric 01/2017
1	SphingolipidsIBA 01/2017
1	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2017
1	SphingomyelinsIBA 01/2017
1	Antipsychotic Agents (Antipsychotics)IBA 01/2017
1	Activating Transcription Factor 4IBA 01/2017
1	Oxygen (Dioxygen)IBA 04/2014
1	Cytostatic AgentsIBA 04/2014
1	FucosyltransferasesIBA 01/2008
1	Pharmaceutical PreparationsIBA 01/2008
1	Estrogens (Estrogen)FDA Link 02/2004
1	Selective Estrogen Receptor Modulators (SERM)IBA 02/2004
1	ZK253IBA 02/2004
1	ZK703IBA 02/2004
1	Tamoxifen FDA LinkGeneric 02/2004
1	Urea (Carbamide)FDA LinkGeneric 02/2004
1	Hormones (Hormone)IBA 02/2004
1	Estrogen ReceptorsIBA 02/2004
1	Estrogen Receptor betaIBA 05/2003

Therapy/Procedure

1	Therapeutics 01/2018
1	Immunotherapy 01/2017
1	Radiotherapy 01/2017
1	Drug Therapy (Chemotherapy) 04/2014
1	Aftercare (After-Treatment) 02/2004